540788
ASPIRA
Start SIP
Invest Now
Start SIP in ASPIRA
Performance
- Low
- ₹60
- High
- ₹64
- 52 Week Low
- ₹50
- 52 Week High
- ₹107
- Open Price₹64
- Previous Close₹64
- Volume6,848
- 50 DMA₹64.42
- 100 DMA₹64.17
- 200 DMA₹63.06
Investment Returns
- Over 1 Month -1.08%
- Over 3 Month + 4.15%
- Over 6 Month -3.98%
- Over 1 Year -8.62%
Smart Investing Starts Here Start SIP with Aspira Pathlab & Diagnostics for Steady Growth!
Aspira Pathlab & Diagnostics Fundamentals Fundamentals refer to the financial data that companies report on a quarterly or annual basis.
- P/E Ratio
- 43.2
- PEG Ratio
- 0.6
- Market Cap Cr
- 63
- P/B Ratio
- 4.4
- Average True Range
- 4.9
- EPS
- -
- Dividend Yield
- 0
- MACD Signal
- -0.07
- RSI
- 44.69
- MFI
- 62.76
Aspira Pathlab & Diagnostics Financials
Aspira Pathlab & Diagnostics Technicals
EMA & SMA
Current Price
₹61.50
-2.89
(-4.49%)
- Bearish Moving Average 16
- Bullish Moving Average 0
- 20 Day
- ₹64.31
- 50 Day
- ₹64.42
- 100 Day
- ₹64.17
- 200 Day
- ₹63.06
Resistance and Support
61.89
- R3 68.15
- R2 66.25
- R1 63.79
- S1 59.43
- S2 57.53
- S3 55.07
Aspira Pathlab & Diagnostics Corporate Actions - Bonus, Splits, Dividends
| Date | Purpose | Remarks |
|---|---|---|
| 2026-02-10 | Quarterly Results | |
| 2025-11-12 | Quarterly Results | |
| 2025-08-12 | Quarterly Results | |
| 2025-05-16 | Audited Results | |
| 2025-02-07 | Quarterly Results |
Aspira Pathlab & Diagnostics F&O
About Aspira Pathlab & Diagnostics
- NSE Symbol
- ASPIRA
- BSE Symbol
- 540788
- Managing Director & CEO
- Dr. Pankaj J Shah
- ISIN
- INE500C01017
Similar Stocks to Aspira Pathlab & Diagnostics
Aspira Pathlab & Diagnostics FAQs
Aspira Pathlab & Diagnostics share price is ₹61 As on 13 February, 2026 | 08:10
The Market Cap of Aspira Pathlab & Diagnostics is ₹63.3 Cr As on 13 February, 2026 | 08:10
The P/E ratio of Aspira Pathlab & Diagnostics is 43.2 As on 13 February, 2026 | 08:10
The PB ratio of Aspira Pathlab & Diagnostics is 4.4 As on 13 February, 2026 | 08:10
Disclaimer: Investment in securities market are subject to market risks, read all the related documents carefully before investing. For detailed disclaimer please Click here.